Furthermore, preferential killing of CD44+/CD24−/low breast cancer cells or BCSCs induced by MET can be sufficient to overcome the primary resistance to Herceptin® in HER2+ breast cancer xenografts. The gene discussed is ERBB2; the disease is breast cancer.